Benny, what are you talking about misinformation.
You are confused, again, about HOW LONG the drug is dosed for, versus HOW SOON it is dosed after injury.
The three hours they talk about in this release is HOW LONG. We don't know the HOW SOON.
As you so often say, this is a new class of drug using a new mechanism of action. There are lots of unknowns. So if NYR-BIO3 needs to be given intravenously within 30 minutes of injury to have a therapeutic effect, then it is not very practical.
If it can be given two hours after injury, or in the field via nasal or other delivery; then it IS very practical.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.18M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.0¢ | $114.5K | 576.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 78460 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 60000 | 2 |
View Market Depth
| Last trade - 15.59pm 16/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |